Corient Private Wealth
ABEO icon

Corient Private Wealth’s Abeona Therapeutics ABEO Stock Holding History

Corient Private Wealth’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$556K Buy
+89,908
New +$494K ﹤0.01% 2150
2025
Q3 		– Sell
-22,416
Closed -$127K – 2552
2025
Q2 		$127K Buy
+22,416
New +$128K ﹤0.01% 2303
2025
Q1 		– Sell
-22,416
Closed -$192 – 2276
2024
Q4 		$192 Hold
22,416
– – ﹤0.01% 2350
2024
Q3 		$142K Buy
22,416
+12
+0.1% +$63 ﹤0.01% 2278
2024
Q2 		$95K Buy
22,404
+8,502
+61% +$43.4K ﹤0.01% 2218
2024
Q1 		$101K Hold
13,902
– – ﹤0.01% 2186
2023
Q4 		$69.6K Hold
13,902
– – ﹤0.01% 2179
2023
Q3 		$58.5K Hold
13,902
– – ﹤0.01% 2068
2023
Q2 		$56K Buy
+13,902
New +$48.6K ﹤0.01% 2015

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Corient Private Wealth's ABEO Position: Q2 2026 in Review

Corient Private Wealth opened a new position in Abeona Therapeutics (ABEO) in Q2 2026: 89,908 shares worth $556K. The stake represents ﹤0.01% of the portfolio and ranks #2150 among its holdings. This is a return to the name: Corient Private Wealth previously reported a position in ABEO as recently as Q2 2025.

Corient Private Wealth first reported a position in ABEO in Q2 2023 and has held it in 9 quarters since. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Corient Private Wealth held 89,908 shares of Abeona Therapeutics worth $556K as of Q2 2026.
  • Abeona Therapeutics was a new Corient Private Wealth position in Q2 2026.
  • Abeona Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2150 holding.
  • Corient Private Wealth first reported a position in Abeona Therapeutics in Q2 2023 and has held it in 9 quarters since.
  • 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.